From: Prospect of cell penetrating peptides in stem cell tracking
Disease | CPP-cargo | Number of enrolled patients | Status | ClinicalTrials.gov ID |
---|---|---|---|---|
Solid tumors | P28 | N = 15 | Phase I completed 2014 | NCT00914914 |
CNS malignancies | P28 | N = 18 | Phase I completed 2017 | NCT01975116 |
Postherpetic neuralgia | TAT-ɛPKC inhibitor | N = 23 | Phase II completed 2011 | NCT01106716 |
Acute inner ear hearing loss | TAT-AM 111 | N = 256 | Phase III completed 2017 | NCT02561091 |
Tumor imaging | ACPPs-Cy5 and Cy7 | N = 27 | Phase I completed 2017 | NCT02391194 |
Cervical dystonia | TAT-Daxibotulinumtoxin A | N = 37 | Phase II completed 2019 | NCT02706795 |
Postoperative ocular inflammation | TAT-XG102 | N = 339 | Phase III completed 2017 | NCT02235272 |